Anti-PD-L1 immobilization on Fe₃O₄ nanocluster-coated AuNR through terpyridine–gadolinium coordination for multimodal imaging and synergistic tumor therapy

IF 5.6 2区医学 Q1 BIOPHYSICS

Colloids and Surfaces B: Biointerfaces Pub Date : 2025-08-14 DOI:10.1016/j.colsurfb.2025.115047

Yue Chen, Yufei Xu, Sihan A, Binbin Shen, Shengwang Zhou

{"title":"Anti-PD-L1 immobilization on Fe₃O₄ nanocluster-coated AuNR through terpyridine–gadolinium coordination for multimodal imaging and synergistic tumor therapy","authors":"Yue Chen, Yufei Xu, Sihan A, Binbin Shen, Shengwang Zhou","doi":"10.1016/j.colsurfb.2025.115047","DOIUrl":null,"url":null,"abstract":"<div><div>Functionalized nanoparticles offer a versatile nanomedicine platform for engineering stimulus-responsive, theranostic drug delivery systems to enhance tumor diagnosis and treatment. Herein, we present the development of a stimulus-responsive Fe₃O₄@AuNR nanotherapeutic platform functionalized with anti-PD-L1, which enables antibody and dual drug loading, tumor-specific controlled release, image-guided combination therapy, and synergistic enhancement of antitumor efficacy. As a biomarker of senescence and tumor progression, β-galactosidase enables 5-FUR-β-Gal prodrug activation, contributing to targeted therapeutic strategies for ovarian cancer. The anti-PD-L1-functionalized Fe₃O₄@AuNR drug delivery system combines chemotherapy, targeted therapy, and photothermal therapy, while simultaneously enabling fluorescence imaging and MRI of tumor tissues, thus providing a synergistic theranostic platform with promising clinical applicability.</div></div>","PeriodicalId":279,"journal":{"name":"Colloids and Surfaces B: Biointerfaces","volume":"256 ","pages":"Article 115047"},"PeriodicalIF":5.6000,"publicationDate":"2025-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Colloids and Surfaces B: Biointerfaces","FirstCategoryId":"1","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0927776525005545","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOPHYSICS","Score":null,"Total":0}

引用次数: 0

Abstract

Functionalized nanoparticles offer a versatile nanomedicine platform for engineering stimulus-responsive, theranostic drug delivery systems to enhance tumor diagnosis and treatment. Herein, we present the development of a stimulus-responsive Fe₃O₄@AuNR nanotherapeutic platform functionalized with anti-PD-L1, which enables antibody and dual drug loading, tumor-specific controlled release, image-guided combination therapy, and synergistic enhancement of antitumor efficacy. As a biomarker of senescence and tumor progression, β-galactosidase enables 5-FUR-β-Gal prodrug activation, contributing to targeted therapeutic strategies for ovarian cancer. The anti-PD-L1-functionalized Fe₃O₄@AuNR drug delivery system combines chemotherapy, targeted therapy, and photothermal therapy, while simultaneously enabling fluorescence imaging and MRI of tumor tissues, thus providing a synergistic theranostic platform with promising clinical applicability.

查看原文本刊更多论文

三联吡啶-钆配位在Fe₃O₄纳米簇包被的AuNR上固定化抗pd - l1用于多模态成像和协同肿瘤治疗

功能化纳米粒子提供了一个多功能的纳米医学平台，用于工程刺激反应，治疗性药物输送系统，以增强肿瘤的诊断和治疗。在此，我们提出了一种具有抗pd - l1功能化的刺激反应性Fe₃O₄@AuNR纳米治疗平台的开发，该平台可以实现抗体和双药负载、肿瘤特异性控释、图像引导联合治疗以及抗肿瘤疗效的协同增强。作为衰老和肿瘤进展的生物标志物，β-半乳糖苷酶能够激活5-FUR-β-Gal前药，有助于卵巢癌的靶向治疗策略。抗pd - l1功能化Fe₃O₄@AuNR给药系统结合化疗、靶向治疗和光热治疗，同时实现肿瘤组织的荧光成像和MRI，提供了一个具有临床应用前景的协同治疗平台。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Colloids and Surfaces B: Biointerfaces 生物-材料科学：生物材料

CiteScore

11.10

自引率

3.40%

发文量

730

审稿时长

42 days

期刊介绍： Colloids and Surfaces B: Biointerfaces is an international journal devoted to fundamental and applied research on colloid and interfacial phenomena in relation to systems of biological origin, having particular relevance to the medical, pharmaceutical, biotechnological, food and cosmetic fields. Submissions that: (1) deal solely with biological phenomena and do not describe the physico-chemical or colloid-chemical background and/or mechanism of the phenomena, and (2) deal solely with colloid/interfacial phenomena and do not have appropriate biological content or relevance, are outside the scope of the journal and will not be considered for publication. The journal publishes regular research papers, reviews, short communications and invited perspective articles, called BioInterface Perspectives. The BioInterface Perspective provide researchers the opportunity to review their own work, as well as provide insight into the work of others that inspired and influenced the author. Regular articles should have a maximum total length of 6,000 words. In addition, a (combined) maximum of 8 normal-sized figures and/or tables is allowed (so for instance 3 tables and 5 figures). For multiple-panel figures each set of two panels equates to one figure. Short communications should not exceed half of the above. It is required to give on the article cover page a short statistical summary of the article listing the total number of words and tables/figures.